Navigation Links
ABR-Affinity BioReagents Finalizes Agreement for Distribution of Osenses Antibodies in the U.S., Canada and Europe
Date:3/3/2008

DENVER and GOLDEN, Colo., March 3 /PRNewswire/ -- ABR-Affinity BioReagents, a leading global antibody manufacturer, announced today the finalization of a reverse distribution agreement with Osenses Pty. Ltd., an Australian-based manufacturer of life science reagents. Further expanding its already extensive portfolio of 100% quality guaranteed research antibodies, ABR is now an authorized distributor of Osenses products in the U.S., Europe and Canada.

Osenses offers primary antibodies for experimental use in the areas of chemosensory receptors (olfactory, vomeronasal and trace amine-associated), and visual, auditory and transient receptors. According to Ken Wilczek, President of ABR-Affinity BioReagents, "Partnering with Osenses enhances our ability to offer experimental research tools to scientists who are active in the increasingly important realm of sensory neuronal research." Encompassing antibodies for olfactory receptors, market proteins and stem cells, the Osenses product line will round out ABR's existing antibody portfolio, which now comprises more than 36,000 quality-guaranteed antibodies and research reagents.

"This type of reverse distribution arrangement allows us to utilize our already strong sales channels to really help get these unique products into the hands of research scientists who are performing cutting edge research on a daily basis," noted Ken Wilczek, President of ABR. Beginning in 2005, ABR-Affinity BioReagents implemented a strategy to investigate and partner with select worldwide antibody suppliers who produce quality products for distribution through ABR into the U.S. Other reverse distribution partners currently include: Abnova, Ab Frontier, Antibody Shop, Good Biotech and Genesis.

About ABR-Affinity BioReagents

Founded in 1989 with world headquarters in Golden, Colorado, ABR-Affinity BioReagents is a world leader in the manufacture and distribution of monoclonal and polyclonal antibodies, kits, recombinant proteins, siRNA, and custom antibody production services, known as Antibody on Demand.

With more than 36,000 antibodies focused in 43 research areas, ABR offers a unique value proposition in the life science industry-research antibodies that are 100% quality guaranteed or your money back-with no questions asked.

Utilizing a distribution network encompassing over 60 nations, ABR products are readily available in every research market on the globe. Products are available directly from ABR in the United States, as well as through an exclusive distribution partnership with Fisher Scientific, a division of Thermo Fisher Scientific.

For additional information about ABR-Affinity BioReagents, contact Leslie Martin with ABR media relations at 1-800-527-4535.


'/>"/>
SOURCE ABR-Affinity BioReagents
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ABR-Affinity BioReagents to Exhibit at ASCB in Washington D.C., December 1 - 5, 2007
2. ABR-Affinity BioReagents Announces Agreements for U.S. Distribution of Research Antibodies
3. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
4. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
5. Touch Bionics signs U.S. distribution agreement with SPS
6. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
10. Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies
11. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):